India’s Peptide Pharma Push Faces Critical Regulatory Hurdles

India’s pharmaceutical sector is making significant strides in peptide drug development, yet it grapples with complex regulatory challenges that could impede progress. At the recent ET Pharma Biomolecule Workshop & Connect in Hyderabad, industry leaders and regulators convened to discuss these obstacles and potential solutions.

Peptide-based therapeutics, known for their structural complexity and immunogenic potential, require rigorous quality control measures. Dr. Suresh Varma Penumathsa of Biological E. Limited emphasized the importance of early-stage aggregation pattern tracking using assays like Thioflavin T to mitigate immunogenicity risks. Dr. Gopal Vaidyanathan from Natco Pharma highlighted the challenges in impurity profiling, noting that while technologies like liquid chromatography and mass spectrometry have advanced, maintaining impurity levels below 0.1% remains demanding.

The financial burden of ensuring Good Manufacturing Practice (GMP) compliance, especially for drugs like GLP-1 with longer amino acid chains, is substantial. Dr. Vaidyanathan pointed out that re-qualification of peptides is not feasible, adding to the complexity. Dr. Manoj Metta of the US Pharmacopeia noted that despite guidelines from agencies like the FDA and EMA, the regulatory landscape for peptides remains intricate.

As India aims to expand its presence in the global peptide market, addressing these regulatory and manufacturing challenges is crucial. The country’s ability to navigate this complex landscape will determine its success in this burgeoning sector.